09 April 2024
09 April 2024
Cadonilimab combination therapy showed improvement in overall survival, progression free survival, duration of response and objective response.
Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.
V-Wave’s Ventura interatrial shunt missed primary endpoint in the pivotal trial but managed to meet the primary safety endpoint.
The NAVIGATE-PF study will enrol 30 subjects across Europe with paroxysmal or persistent atrial fibrillation (AF).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
